Rituximab in IgA Nephropathy: The RITA Multicenter Randomized Trial.
Standard kidney-protection therapy remains the best available option for IgA nephropathy, as adding rituximab didn't improve outcomes in this major trial.
This PubMed-indexed study examined rituximab in iga nephropathy: the rita multicenter randomized trial. No additional reduction in proteinuria or preservation of kidney function was observed with the addition of RTX to optimized RASI-based therapy in patients with IgAN FUNDING: Grants from government (National Key Research and Development Program, Major International [Regional] Joint Research Program of China, National Natural Science Foundation of China, National Facility for Translational Medicine [Shanghai], Shanghai 'Rising Stars of Medical Talent' Youth Development Program), academic (Shanghai Shenkang Hospital Development Center), and non-profit (International Society of Nephrology) sources.
What the study was
- Study design
- Multicenter randomized controlled trial
- Population
- Human participants or human evidence described in the PubMed abstract
- Sample size
- 106
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- American journal of kidney diseases : the official journal of the National Kidney Foundation
Why it surfaced
Multicenter randomized controlled trial with PubMed abstract evidence; scored conservatively for treatment innovation relevance and evidence maturity.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.